Home » Stocks » CTMX

CytomX Therapeutics, Inc. (CTMX)

Stock Price: $7.45 USD 0.10 (1.36%)
Updated November 27, 11:51 AM EST - Market open

Stock Price Chart

Key Info

Market Cap 344.37M
Revenue (ttm) 92.27M
Net Income (ttm) -53.64M
Shares Out 46.22M
EPS (ttm) -1.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $7.45
Previous Close $7.35
Change ($) 0.10
Change (%) 1.36%
Day's Open 7.37
Day's Range 7.30 - 7.47
Day's Volume 95,813
52-Week Range 3.60 - 15.44

More Stats

Market Cap 344.37M
Enterprise Value 44.90M
Earnings Date (est) Mar 4, 2021
Ex-Dividend Date n/a
Shares Outstanding 46.22M
Float 44.92M
EPS (basic) -1.18
EPS (diluted) -1.17
FCF / Share -0.20
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.95M
Short Ratio 9.06
Short % of Float 8.80%
Beta 0.69
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3.73
PB Ratio 7.10
Revenue 92.27M
Operating Income -71.21M
Net Income -53.64M
Free Cash Flow -9.36M
Net Cash 299.47M
Net Cash / Share 6.48
Gross Margin 62.31%
Operating Margin -77.17%
Profit Margin -58.10%
FCF Margin -10.14%
ROA -11.90%
ROE -82.41%
ROIC -61.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (10)

Buy 6
Overweight 0
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(68.59% upside)
Current: $7.45
Target: 12.56
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-3.38%-16.92%376.12%95.06%51.9%471.73%-
Gross Profit57.4959.5071.6215.047.715.080.89
Operating Income-111-77.87-46.26-59.59-33.20-29.77-14.96
Net Income-102-84.60-43.10-58.90-35.37-30.31-15.14
Shares Outstanding45.3441.6637.1736.238.600.990.77
Earnings Per Share-2.26-2.03-1.16-1.63-4.90-35.25-24.46
Operating Cash Flow-140-75.52170-2.03-27.4231.80-8.01
Capital Expenditures-3.50-3.79-1.56-2.12-1.59-1.66-0.73
Free Cash Flow-144-79.31169-4.16-29.0130.14-8.74
Cash & Equivalents29743737518318864.50-
Total Debt24.87----2.99-
Net Cash / Debt27243737518318861.51-
Book Value51.1113169.9078.48126-78.54-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name CytomX Therapeutics, Inc.
Country United States
Employees 158
CEO Sean A. McCarthy

Stock Information

Ticker Symbol CTMX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CTMX
IPO Date October 8, 2015


CytomX Therapeutics operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug for the treatment of metastatic melanoma; CX-2029, a PDC targeting CD71 for solid tumors; and BMS-986288, an anti-CTLA-4 Probody drug for solid tumors. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.